[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) >> Individual ID:PBN__RiskMitigation_1860 

# __Conduct more efficacy studies in clinical settings to evaluate the impact of these measures on tb transmission__

## Category to which it belongs

* [Implement comprehensive, widespread testing and contact tracing programs to monitor and control the spread of the virus.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_460.md)

## Closest similar item

* [Conduct further research and studies on the effectiveness of uvgi in preventing tuberculosis transmission](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2321.md)
* [Promote awareness about asymptomatic transmission, encourage individuals to practice preventive measures regardless of symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2312.md)
* [Combined use of wbe followed by clinical testing](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1204.md)
* [Improve vaccine efficacy through research and development.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2509.md)
* [Evaluate efficacy differences based on symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1186.md)
* [Conduct comparative studies on disease severity between re-infected and initially infected patients.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2512.md)
* [Conducting research studies and gathering quantitative data on the outcomes and effectiveness of ubpi.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2917.md)
* [Increase testing capacity to include testing of mild or asymptomatic individuals to obtain a more accurate assessment of the prevalence.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2560.md)
* [Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2513.md)
* [Improve reporting standards and conduct high-quality research studies on preventive interventions.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2068.md)

## Risks possibly mitigated by this Mitigation

* [Absence of efficacy studies in clinical settings](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1359.md)

